SCHEMBL14058665

SCHEMBL14058665

CC(=O)N1N=C(c2ccc(NS(=O)(=O)c3ccc(F)cc3)cc2)CC1c1ccc(C)cc1

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PTGS2 P35354 2/20 0.71
▸ HPGD P15428 2/20 0.67
▸ MAOA P21397 2/20 0.62
▸ MAOB P27338 2/20 0.62
▸ NT5E P21589 1/20 0.62
▸ CA12 O43570 3/20 0.61
▸ CA1 P00915 3/20 0.61
▸ CA2 P00918 3/20 0.61
▸ CA9 Q16790 3/20 0.61
▸ ACHE P22303 1/20 0.61
▸ BCL2 P10415 1/20 0.61
▸ BECN1 Q14457 1/20 0.61
▸ EGFR P00533 1/20 0.60
▸ KDM4E B2RXH2 3/20 0.60
▸ GLA P06280 3/20 0.60
▸ ALDH1A1 P00352 2/20 0.60
▸ GAA P10253 2/20 0.60
▸ PKM P14618 2/20 0.60
▸ MAPT P10636 1/20 0.57
▸ CACNA1H O95180 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14058664 1.00 PTGS2 (0.71) PTGS2HPGDMAOAMAOBNT5E
SCHEMBL14058294 0.96 PTGS2 (0.77) PTGS2HPGDNT5ECA12CA1
SCHEMBL14136234 0.95 PTGS2 (0.76) PTGS2HPGDMAOAMAOBCA12
SCHEMBL14058011 0.91 PTGS2 (0.70) PTGS2HPGDNT5ECA12CA1
SCHEMBL14058064 0.91 PTGS2 (0.70) PTGS2MAOAMAOBNT5ECA12
SCHEMBL14058010 0.91 PTGS2 (0.70) PTGS2HPGDNT5ECA12CA1
SCHEMBL14136239 0.90 PTGS2 (0.71) PTGS2HPGDMAOAMAOBCA12
SCHEMBL14133994 0.90 ACHE (0.72) PTGS2HPGDMAOAMAOBNT5E
SCHEMBL14136238 0.90 ACHE (0.69) PTGS2HPGDMAOAMAOBNT5E
SCHEMBL14058334 0.90 PTGS2 (0.71) PTGS2MAOAMAOBNT5ECA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2012160447-A1 3, 5 -DIPHENYL- SUBSTITUTED PYRAZOLINES FOR THE TREATMENT OF CANCER, PROLIFERATIVE, INFLAMMATORY OR AUTOIMMUNE DISEASES DYNAMIX PHARMACEUTICALS LTD. (IL) 2012-11-29 — — WO disclosed
US-20120302609-A1 Pyrazolines for the Modulation of PKM2 DYNAMIX PHARMACEUTICALS LTD. (IL) 2012-11-29 — — US disclosed
US-20120302609-A1 Pyrazolines for the Modulation of PKM2 DYNAMIX PHARMACEUTICALS LTD. (IL) 2012-11-29 — — US disclosed
WO-2012160447-A1 3, 5 -DIPHENYL- SUBSTITUTED PYRAZOLINES FOR THE TREATMENT OF CANCER, PROLIFERATIVE, INFLAMMATORY OR AUTOIMMUNE DISEASES DYNAMIX PHARMACEUTICALS LTD. (IL) 2012-11-29 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120302609-A1 Pyrazolines for the Modulation of PKM2 PDK2, PDK4, PDK3 PTGS2 1275/4885HPGD 977/4885MAOA 4254/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback